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302Introduction: In Europe and the United States, verteporﬁn (Visudyne; VP) is registered and used in treating
macular degeneration. Research showed that VP decreased expression of ﬁbrotic genes in ﬁbroblasts collected
from nodules of patients suffering from Dupuytren’s disease, plausibly by de-activating transcription in the Yes
Activated Protein (YAP) pathway.
Aim: To analyze the effect of VP on myoﬁbroblasts cultured from Peyronie’s disease (PD) plaques.
Methods: At surgery for PD we took biopsies from the plaques of 5 patients. By immunostaining, the presence of
the pathologic myoﬁbroblasts was determined. After culturing cells, VP was dispensed in starvation medium for 24
and 48 hours and messenger(m)RNA levels of COL1A1, ACTA2, COL5A1, EDA-FN, LOXL2, CCN2, SER-
PINH1, PLOD2, and YAP were quantiﬁed and compared with controls with real-time polymerase chain reaction.
Main Outcome Measure: mRNA-levels of COL1A1, ACTA2, COL5A1, EDA-FN, LOXL2, CCN2,
SERPINH1, PLOD2, and YAP.
Results: The pathologic phenotype of cells isolated from PD plaques was conﬁrmed with baseline immuno-
ﬂuorescent stainings that showed considerable levels of a-smooth muscle actin, being a marker for the presence of
myoﬁbroblasts. The mRNA ratios of all the genes related to ﬁbrosis (COL1A1, etc.) except YAP decreased
signiﬁcantly after treatment with VP within 24 and 48 hours. These results suggest inhibition of ﬁbrosis in the
YAP cascade, downstream of YAP.
Conclusion: In our opinion, urologists must move the focus to disease before deformity, and the search for new
oral or intralesional agents, well-tolerated and effective in both the acute and chronic phase of PD must continue.
VP blocked the expression of genes related to ﬁbrosis in the YAP cascade in myoﬁbroblasts derived from PD
plaque. Mohede DCJ, de Jong IJ, Bank RA, et al. Verteporﬁn as a medical treatment in Peyronie’s disease.
Sex Med 2018;6:302e308.
Copyright  2018, The Authors. Published by Elsevier Inc. on behalf of the International Society for Sexual Medicine.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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In 1743, François Gigot de la Peyronie (1678e1747) ﬁrst
provided a comprehensive description of induratio penis plastic,
now known as Peyronie’s disease (PD).1 PD is a benign ﬁbro-
proliferative disorder of the penis, which causes the formation of
a plaque in the tunica albuginea. Many pharmacologic optionsly 9, 2018. Accepted August 26, 2018.
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rg/10.1016/j.esxm.2018.08.002have been proposed, but until now none has received a grade-A
recommendation. Currently, collagenase from Clostridium his-
tolyticum is the only drug approved by the American and Eu-
ropean authorities for intralesional injection in patients with
dorsal or dorsolateral curvature >30 with a palpable plaque. In
the Netherlands the prescription of oral drugs for PD, for
example pentoxifylline, is only allowed if one informs the patient
about its off-label use and possible adverse events.
Verteporﬁn (trade name Visudyne; VP) is registered in the
United States and Europe as a sensitizer for photodynamic therapy
to eradicate abnormal blood vessels in the eye associated with the
wet form of macular degeneration. The ﬁrst report on photody-
namic therapy with VP for choroidal neovascularization was
published in 1999.2 VP accumulates in the abnormal blood ves-
sels. When stimulated by non-thermal red light (wavelength 693
nm) in the presence of oxygen, VP produces reactive short-livedSex Med 2018;6:302e308
Figure 1. Simpliﬁed ﬁbrosis-related processes in the Yes Activated Protein (YAP) cascade. As a result of microtrauma and genetic
susceptibility, the YAP cascade comes into force causing extracellular matrix synthesis, myoﬁbroblast differentiation, apoptosis resistance,
migration, and proliferation. These ﬁbrotic processes lead up to plaque development and subsequent penile deformity. In red, verteporﬁn’s
assumed point of engagement in the cascade. In boldface, markers of the different ﬁbrotic processes.
Verteporﬁn Blocks Fibrosis-Related Genes in yhe YAP Cascade 303singlet oxygen and other oxygen radicals, locally damaging the
endothelium and resulting in blockage of these vessels. In its
inactivated form (ie, VP that is not subjected to photo irradiation),
VP is a small molecular inhibitor of the Hippo-Yes Activated
Protein (YAP) pathway (Figure 1) and considered a promising
drug in the treatment of pancreatic cancer.3 In that respect it is
relevant to mention that Scandinavian studies showed that pa-
tients with Dupuytren’s disease (DD) in this part of the world
have greater incidences of a variety of smoking-related diseases
such as pancreatic, buccal, and lung cancer.4e6 DD and its related
diseases are also a burden for societies in other parts of the world.7
Especially severe and younger-onset cases may be subject to
increased cancer incidence and mortality.8,9
Inactive VP attenuates renal ﬁbrosis in mice subjected to
unilateral ureteral obstruction, probably by blocking the tran-
scriptional activation of targets in the YAP cascade involved in
ﬁbrosis-related processes.10 The objective of our study was to
determine whether VP would have similar effects on (myo)ﬁ-
broblasts derived from plaques in patients with PD (being the
cells responsible for the production of ﬁbrotic lesions).MATERIALS AND METHODS
Ethics Statement
Plaque tissue samples of PD patients were collected after
obtaining informed written consent of the patients; our protocol
was approved by the Medical Ethics Committee (METc) of the
University Medical Center Groningen (2007/067; UMCG), in
accordance with the Declaration of Helsinki.Sex Med 2018;6:302e308Primary Tissues
Plaque tissues were obtained from 5 PD patients with primary
disease that underwent plaque incision and grafting or a Nesbit
procedure by a senior urologist (M.F.vD.) in the University
Medical Center Groningen.Cell Culture Conditions
(Myo)ﬁbroblasts were obtained from dissected plaque tissue
by culturing the small pieces in Dulbecco’s Modiﬁed Eagle’s
Medium (DMEM; Lonza Group, Basel, Switzerland) containing
1% L-glutamine, 1% penicillin-streptomycin, and 10% fetal
bovine serum (FBS) at 37oC in a 5% CO2 incubator. Experi-
ments were performed on cells from the 8th passage to a new
culturing-ﬂask. To conﬁrm the presence of myoﬁbroblasts (ie,
activated ﬁbroblasts), immunoﬂuorescent staining for an alpha-
smooth muscle actin (a-SMA) was performed before starting
the VP experiments.VP Experiment
Starvation of the cells took place for 16 hours overnight in
culture medium consisting of DMEM containing 1% penicillin/
streptomycin, 1% L-glutamine, 0.5% FBS, and 17 mM ascorbic
acid. Cells were kept at 37C in 5% CO2. 1 day after starvation,
the cells were exposed to VP (250 nM) in the previously
mentioned culture medium containing 0.01% (volume/volume
[v/v]) dimethyl sulfoxide (DMSO; this was used as solvation
vehicle for VP). The control group was exposed to 0.01% (v/v)
DMSO. Lights were off when working with either VP or
Table 1. Sequences of the used primers
Primers Sequence











Sequences in 5’ to 3’ direction.
A ¼ adenine; C ¼ cytosine; F ¼ forward; G ¼ guanine; R ¼ reversed; T ¼ thymine.
304 Mohede et alDMSO. The treatment took place for 24 and 48 hours in an
incubator at 37C in 5% CO2.Immunostaining
After treatment, cells were ﬁxated in 1:1 acetone/methanol.
The cells were then permeabilized with 0.5% Triton X-100 in
phosphate-buffered saline (PBS), incubated with 10% serum of
the secondary species and blocked with 1% bovine serum al-
bumin (BSA) in PBS. Primary antibodies directed toward a
(Dako M0851 IgG2a) were diluted in 1% BSA in PBS and
incubated for 1 hour at room temperature. Secondary antibodies
(GaMIgG2a-biotin) were diluted in 2% normal human serum in
PBS and incubated for 30 min at room temperature, covered inFigure 2. Characterization of Peyronie’s Disease (PD) plaque cells (pa
indicating the presence of activated cells in the PD plaques; red a-smo
represents 50 mm.tin foil. Cells were then incubated with 1:100 streptavidin-Cy3
in 1:5,000 4’,6-diamidino-2-phenylindole (DAPI) in tin foil
for 30 minutes at room temperature. DAPI was used to stain the
nuclei. After every incubation step a washing step was performed,
incubating the cells in fresh PBS 3 times for 5 minutes. Pictures
were taken under a ﬂuorescence microscope.Real-Time Polymerase Chain Reaction
After treatment, cells were lysed and stored in 350 ml of a mix
with dithiothreitol (DTT) and FARB Buffer (10 ml DTT per 1
ml FARB Buffer) at -80C. RNA was isolated using an RNA
isolation kit (FavorPrep mini kit, Favorgen Biotech Corp., Ping-
Tung, Taiwan) according to the manufacturer’s instructions.ssage 8). Part of the ﬁbroblasts showed features of myoﬁbroblasts,
oth muscle actin, blue 6-diamidino-2-phenylindole. Black scale bar
Sex Med 2018;6:302e308
Figure 3. Response of (myo)ﬁbroblasts subjected to 250 nM verteporﬁn (VP) for 24 and 48 hours. mRNA levels of Yes Activated Protein
did not change, whereas mRNA levels of extracellular matrix molecules (COL1A1, COL5A1, EDA-FN), collagen-modifying enzymes
(SERPINH1, PLOD2, LOXL2), and the pro-ﬁbrotic markers CCN2 and ACTA2 were attenuated by VP. * ¼ P < .05.
Verteporﬁn Blocks Fibrosis-Related Genes in yhe YAP Cascade 305Complementary DNA (cDNA) was synthesized by priming
with random hexamer primer (1 ml added to 11 ml concentrated
RNA). After adding the primer, cells were incubated for 5 min in
65C. A mixture of 4 ml reaction buffer 5x, 2 ml dNTP’S
(Qiagen, Stokach, Germany) (10 mM) mixture, 0.5 ml RiboLock
RNAse inhibitor (Thermo Fisher Scientiﬁc, Waltham, MA,
USA), 0.5 ml RNAse free H2O, and 1 ml Reverse Transcriptase
RevertAid M-MuLV (Thermo Fisher Scientiﬁc, Waltham, MA,
USA) was then added to each sample, making a total volume of
20 ml. Cells were subsequently incubated according to the next
program: 5 minutes at 25C; 60 minutes at 42C; 5 minutes at
70C; and stored at -20oC. For real-time polymerase chain re-
action, triplicates of each sample were used.
Primers (Table 1) were dissolved in Milli-Q water (Merck,
Darmstadt, Germany), needing 0.25 ml of both forward and
reverse primer per reaction (150 nM/primer). Mastermix
(Thermo Fisher Scientiﬁc, Waltham, MA, USA) per gene con-
tains 5 ml SYBRgreen (Rouche; 2x) and 0.5 ml Prime Mix (6
mM). 5 ml diluted cDNA sample (5 ng/ml) and 5 ml Mastermix
were added to each well in a 384 well plate, making a total
volume of 10 ml. Plates were run on the ViiA 7 Real-Time PCR
system (Thermo Fisher Scientiﬁc, Waltham, MA, USA). The
relative gene expression was calculated using the DDCt method,
normalizing for the average expression of the household gene
YWHAZ.Sex Med 2018;6:302e308Statistics
Experiments were performed in triplicate. Statistics were
performed using GraphPad Prism Software version 7 (GraphPad
Software, La Jolla, CA, USA). A Kruskal-Wallis test was used to
determine whether there were differences in ranks between the 3
groups. 2-way ANOVA with Bonferroni posttest was used for
statistics; P < .05 was considered signiﬁcant.RESULTS
Characterization of PD Plaque Cells
To conﬁrm the pathologic phenotype of cells isolated from
PD plaques, baseline immunoﬂuorescent stainings were per-
formed that showed considerable levels of a-SMA, being a
marker for the presence of myoﬁbroblasts (Figure 2). This
ﬁnding conﬁrmed the pathologic nature of the obtained plaque
samples.Gene Expression of Fibrosis-Related Genes
Myoﬁbroblasts derived from the plaque tissue responded to VP
treatment for both 24 and 48 hours, resulting in signiﬁcant de-
creases in gene expression levels of CCN2, COL1A1, COL5A1,
EDA-FN, PLOD2, and LOXL2 (Figure 3). The mRNA level of
SERPINH1 was decreased only at 48 hours, whereas that of
ACTA2 was reduced at 24 hours only (Figure 2). As expected, VP
Figure 4. Response of (myo)ﬁbroblasts subjected to 250 nM verteporﬁn (VP) as a percent difference after 24 and 48 hours. Compared
with 24 hours, the mRNA level of EDA-FN and SERPINH1 was even more decreased at 48 hours, showing that VP has long-lasting anti-
ﬁbrotic effects. * ¼ P < .05.
306 Mohede et aldid not affect mRNA levels of YAP. The control group (DMSO
only) did not differ from the control group withoutDMSO, which
showed that DMSO did not affect the cultures (data not shown).Compared with 24 hours, the mRNA level of EDA-FN and
SERPINH1 was even more decreased at 48 hours, showing that
VP has long-lasting anti-ﬁbrotic effects (Figure 4).Sex Med 2018;6:302e308
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VP’s Role in Fibrosis
The lack of effective medical treatments for PD stems from a
lack of understanding of its biology. However, today it is well
known that tissue derived from PD plaques contains myoﬁbro-
blasts, the cells responsible for the pathologic ﬁbrotic processes.
Indeed, we found considerable amounts of myoﬁbroblasts in our
cell cultures derived from plaques. Furthermore, our study shows
that in vitro exposure of VP to (myo)ﬁbroblasts inhibits the
pathologic processes by means of the down-regulation of ﬁbrosis-
associated genes. Fibrosis is characterized by excessive produc-
tion, deposition, and contraction of extracellular matrix (ECM),
leading to signiﬁcant organ dysfunction.11 Here we show that VP
is able to reduce the expression of the 2 major ﬁbrillary collagens,
that is, collagen type I and type V, and the ECM component
ﬁbronectin (EDA-FN). This should lead to a less-excessive
deposition of ECM. It also helps that VP is able to decrease
SERPINH1 levels (also known as HSP47), a chaperone needed
for the proper transportation of collagen. In ﬁbrosis the ECM
stiffens, even before scarring occurs, owing to an increased
expression of enzymes involved in collagen cross-linking. In our
study we found that the expression of at least 2 of these enzymes,
LOXL2 and PLOD2, is inhibited by VP. This should lead to a
less-stiff ECM. In addition, collagen cross-linked by hydrox-
ylysine residues mediated by PLOD2 is more difﬁcult to degrade
by matrix metalloproteinases.12 Lower cross-links levels derived
from PLOD2 most likely results in a faster degradation of
collagen molecules, resulting in less ECM accumulation. Our
ﬁndings suggest that VP might beneﬁt patients mostly in the
acute phase of PD, but possibly also in the chronic phase.
However important some of these mechanisms in certain ma-
lignancies are, our main foci for this study were PD and ﬁbrosis-
related processes.Pharmacokinetics and Safety
For its current indication (ie, macular degeneration), VP is
administered parenterally in the largest possible arm vein in a
dose of 6 mg/m2 and light-activated. This can be repeated yearly
4 times. No drugedrug interactions were ever described in pa-
tients treated with VP, but simultaneous use of photo-
sensibilizing drugs such as tetracyclines and thiazide diuretics
may increase the risk of light-sensitivity reactions. Porphyria is an
absolute contraindication. During 48 hours, patients are
photosensitive and advised not to come in contact with direct
bright (sun)light and to cover themselves with sunglasses and
clothes.13 In animal studies, mild extravascular hemolysis and
hematopoiesis were noted in inactivated daily doses 32e70 times
(in dogs and rats) as high as advised in humans when adminis-
tered for 4 weeks.14 Fast admission of 2.0 mg/kg in pigs under
general anesthesia led to hemodynamic instability and diphen-
hydramine decreased these effects, suggesting histamine-related
processes. Animal studies ruled out ocular toxicity. There was
no teratogenicity reported in rabid fetuses that received 67 timesSex Med 2018;6:302e308the advised dosage in humans and no toxicity was seen in general
genotoxic tests. In mice, beneﬁcial effects were reported in
immune-mediated diseases. Normal immune reactions in the
skin were decreased without causing skin reactivity or generalized
non-speciﬁc immune suppression. An overview of preliminary
clinical studies showed that VP was safe in humans with only
minimal side effects.15 Because VP is already FDA approved,
testing it as an off-label treatment for PD may be an interesting
step, but future research can better be focused on optimal
administration and dosage schemes for possible treatment of PD.
Until now orally administered VP has not been tested, because
parenteral administration is preferred for its current indication.
None of the options depicted in the European guidelines carry
a grade-A recommendation, but their assumed working mecha-
nisms are worth taking into account considering the quest for
new treatment strategies.16 Combination therapy with histori-
cally proposed medical methods and up-and-coming ones such as
verteporﬁn inhibiting disease-related processes on different levels,
can be considered for future trials. In that respect, we strongly
recommend a close collaboration with biologists and experts in
PD-related ﬁbrotic diseases.
RECOMMENDATIONS AND CONCLUSION
Regarding PD, urologists should focus on the disease before
deformity, preferably in an internationally collaborative fashion.
The search for new oral and intralesional agents, well tolerated
and effective in both the acute and chronic phase of PD, should
be encouraged. As in DD, new PD lab models (eg,
3-dimensional cell cultures) may be used to ﬁnd novel thera-
peutic targets. To achieve these models, one obviously needs
basic researchers. Human tissue-engineered models have already
begun replacing animal models for preclinical drug testing.17
Urologists with special interest in PD should organize brain-
storming symposia with non-urologists such as biologists and
geneticists. Improved international collaboration will pave the
way for funding and ﬁnding optimal research paths.
In the end, the management of patients with PD undoubtedly
will improve, with fewer needing surgery. In this respect verte-
porﬁn is one of the drugs that needs further investigation, because
it apparently displays a wide spectrum of anti-ﬁbrotic properties.ACKNOWLEDGMENTS
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